MENU

Researchers Awarded Grant to Study Use of Lipitor in Patients With Lynch Syndrome

March 3, 2021

PHILADELPHIA (March 3, 2021)—Margie L. Clapper, PhD, co-leader of Fox Chase Cancer Center’s Cancer Prevention and Control Program, has been awarded a grant by the Prevent Cancer Foundation to investigate the use of atorvastatin, also known by the brand name Lipitor, to prevent cancer in patients with Lynch syndrome. Clapper will be working with Michael J. Hall, MD, MS, co-leader of Fox Chase’s Cancer Prevention and Control Program, on the project. 

Lynch syndrome is an inherited disorder that increases a patients’ risk of multiple types of cancer. Colorectal cancer is one of the most common in patients with this syndrome, with a lifetime risk of up to 80% in those with the genetic mutation.

“Many of these folks have lived through years of seeing parents and siblings develop one and sometimes many cancers, and this is terrifying,” said Hall. “If a once-a-day common medication like atorvastatin can help lower risk by even 20% or 30%, that’s well worth it for most of these folks.”

Currently the only cancer prevention regimen available to Lynch syndrome patients involves taking high doses of aspirin on a daily basis. However, as research has shown, aspirin, particularly when high doses are taken over a long period of time, can cause gastrointestinal bleeding and other high-risk side effects. Clapper and Hall believe atorvastatin can be a safer option.

Their study began with animal-based colon cancer research in Clapper’s lab. There they found that if, through colonoscopies, they first identified which mice had already developed polyps (i.e., precancerous growths), the researchers could tailor treatment to be more effective.

Dr. Margie ClapperDr. Margie Clapper

Dr. Michael HallDr. Michael Hall

In animals that were polyp-free, atorvastatin showed a chemopreventive, antitumor effect. If the animal had a polyp, atorvastatin was only effective when combined with a nonsteroidal anti-inflammatory agent.

To advance this research and see whether atorvastatin with or without aspirin could help to prevent colon cancer in humans, Clapper has joined forces with Hall, who treats a large Lynch syndrome population.

“The beauty of this research is that it’s translational,” said Clapper. “You actually go from the bench to the bedside.”

The Lynch syndrome population is ideal for this study, because the researchers need individuals who are high-risk but have not yet developed polyps or tumors. Patients who elect to participate in the study are stratified based on the results of their routine colonoscopy. If they don’t have any abnormal growths, they are given atorvastatin for six weeks. If they are found to have a polyp or cancer, they are given a combination of atorvastatin and aspirin for the same length of time.

After six weeks, investigators will take colon biopsies to check for biomarkers, which are indicators in the tissues that the therapy is having an antitumor effect.

This study, “Impact of Atorvastatin With or Without Aspirin on Colorectal Biomarkers in Patients with Lynch Syndrome: A Pilot Study,” is currently in progress, with nearly 60% of the target population already enrolled. Funds will be used to assess the effectiveness of the drugs in colon tissue samples.

The resulting data are expected to accelerate the early stage development of a novel preventive option for patients who face a very high lifetime risk of colorectal cancer. The study’s goal is closely aligned with the Prevent Cancer Foundation’s vision to “Stop Cancer Before It Starts” using primary and secondary prevention strategies.

For more information about Fox Chase’s clinical trials, please call 215-214-1515 or visit the clinical trials section of our website.

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase